GSTM1 and chronic kidney disease: Potential clinical benefits of HIF-PHIs therapy include: achieving Hb target with a 5–17-fold lower plasma EPO levels relative to those receiving ESA; and a lipid-lowering effect, blood-pressure reduction, anti-inflammatory effects, protection from ischemic injuries, and protective effects with regard to CKD [5,92,93,94,95,96,97,98].